Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.49 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.49 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.49 |
| ▸ | DRD3 | P35462 | 2/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.49 |
| ▸ | HTR1A | P08908 | 1/20 | 0.49 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.49 |
| ▸ | DRD1 | P21728 | 1/20 | 0.49 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.49 |
| ▸ | ACHE | P22303 | 1/20 | 0.49 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.49 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.49 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.49 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.49 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.49 |
| ▸ | SLC6A11 | P48066 | 4/20 | 0.48 |
| ▸ | SLC6A12 | P48065 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Maleic Acid SCHEMBL29410667 | 0.90 | SLC6A11 (0.49) | ALDH1A1HPGDHSD17B10CHRM2ADRA2A | |
| SCHEMBL332237 | 0.82 | TSHR (0.52) | ALDH1A1CHRM2ADRA2AADRA1ADRD3 | |
| SCHEMBL13073639 | 0.72 | SLC6A1 (0.46) | ALDH1A1DRD3SLC6A11SLC6A12KMT2A | |
| SCHEMBL3979002 | 0.72 | SIGMAR1 (0.63) | ALDH1A1HPGDHSD17B10KMT2ALMNA | |
| SCHEMBL10366646 | 0.70 | KDM4E (0.61) | ALDH1A1HPGDHSD17B10DRD3HTR1A | |
| SCHEMBL13073640 | 0.70 | SLC6A1 (0.44) | ALDH1A1SLC6A11SLC6A12KMT2ALMNA | |
| SCHEMBL11496587 | 0.70 | LMNA (0.53) | ALDH1A1HPGDHSD17B10SLC6A4SLC6A3 | |
| SCHEMBL11486298 | 0.70 | ALDH1A1 (0.47) | ALDH1A1HPGDHSD17B10SLC6A4SLC6A3 | |
| SCHEMBL8070876 | 0.68 | LSS (0.63) | ALDH1A1HPGDHSD17B10HRH3KMT2A | |
| SCHEMBL7282583 | 0.67 | HRH1 (0.67) | ALDH1A1HPGDHSD17B10CHRM2ADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 115 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160067264-A1 | MEDICAMENT AND METHOD OF DIAGNOSIS | UNIVERSITY OF SHEFFIELD (GB) | 2016-03-10 | — | — | US | claimed |
| US-20140170768-A1 | METHOD FOR MONITORING AND ASSESSING PITUITARY FUNCTION | I-CALQ LLC | 2014-06-19 | — | — | US | claimed |
| EP-2532350-A1 | Pharmaceutical combination of a glucocorticoid receptor antagonist and a cortisol synthesis inhibitor for treating cushing's syndrome | Laboratoire HRA Pharma (FR) | 2012-12-12 | — | — | EP | claimed |
| US-20110224179-A1 | MEDICAMENT AND METHOD OF DIAGNOSIS | UNIVERSITY OF SHEFFIELD (GB) | 2011-09-15 | — | — | US | claimed |
| US-20100261693-A1 | METHOD FOR TREATING CUSHING'S SYNDROME | LABORATOIRE HRA PHARMA (FR) | 2010-10-14 | — | — | US | claimed |
| EP-2211845-A2 | GLUCOCORTICOID RECEPTOR ANTAGONISTS SUCH AS MIFEPRISTONE FOR TREATING CUSHING'S SYNDROME | Laboratoire HRA Pharma (FR) | 2010-08-04 | — | — | EP | claimed |
| US-20100179115-A1 | USE OF A GLUCOCORTICOID RECEPTOR II ANTAGONIST TO TREAT DEPRESSION IN PATIENTS TAKING IL-2 | CORCEPT THERAPEUTICS, INC. (US) | 2010-07-15 | — | — | US | claimed |
| WO-2009050136-A2 | GLUCOCORTICOID RECEPTOR ANTAGONISTS SUCH AS MIFEPRISTONE FOR TREATING CUSHING' S SYNDROME | LABORATOIRE HRA PHARMA (FR) | 2009-04-23 | — | — | WO | claimed |
| EP-2012796-A2 | THE USE OF A GLUCOCORTICOID RECEPTOR II ANTAGONIST TO TREAT DEPRESSION IN PATIENTS TAKING IL-2 | Corcept Therapeutics, Inc. (US) | 2009-01-14 | — | — | EP | claimed |
| WO-2007131041-A2 | THE USE OF A GLUCOCORTICOID RECEPTOR II ANTAGONIST TO TREAT DEPRESSION IN PATIENTS TAKING IL-2 | CORCEPT THERAPEUTICS, INC. (US) | 2007-11-15 | — | — | WO | claimed |
| US-20020065259-A1 | Glucocorticoid blocking agents for increasing blood-brain barrier permeability | BIOPHARMA SECURED DEBT FUND II SUB, S.AR.L (LU) | 2002-05-30 | — | — | US | claimed |
| WO-2002040018-A1 | TREATMENT OF GLAUCOMA AND OCULAR HYPERTENSION | ALCON, INC. (CH) | 2002-05-23 | — | — | WO | claimed |
| WO-2002017930-A2 | GLUCOCORTICOID BLOCKING AGENTS FOR INCREASING BLOOD-BRAIN BARRIER PERMEABILITY | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2002-03-07 | — | — | WO | claimed |
| US-6177427-B1 | NON-STEROIDAL GLUCOCORTICOID ANTAGONISTS | ALCON LABORATORIES, INC. | 2001-01-23 | — | — | US | claimed |
| EP-1047410-A1 | TREATMENT OF GLC1A GLAUCOMA WITH NON-STEROIDAL GLUCOCORTICOID ANTAGONISTS | ALCON LABORATORIES, INC. (US) | 2000-11-02 | — | — | EP | claimed |
| US-6051573-A | Treatment of GLC1A glaucoma with non-steroidal glucocorticoid antagonists | ALCON LABORATORIES, INC. (US) | 2000-04-18 | — | — | US | claimed |
| WO-1999032101-A1 | TREATMENT OF GLC1A GLAUCOMA WITH NON-STEROIDAL GLUCOCORTICOID ANTAGONISTS | ALCON LABORATORIES, INC. (US) | 1999-07-01 | — | — | WO | claimed |
| US-11969435-B2 | Concomitant administration of glucocorticoid receptor modulators and CYP3A inhibitors | CORCEPT THERAPEUTICS, INC. (US) | 2024-04-30 | — | — | US | disclosed |
| US-6051573-A | Treatment of GLC1A glaucoma with non-steroidal glucocorticoid antagonists | ALCON LABORATORIES, INC. (US) | 2000-04-18 | — | — | US | disclosed |
| WO-1999032101-A1 | TREATMENT OF GLC1A GLAUCOMA WITH NON-STEROIDAL GLUCOCORTICOID ANTAGONISTS | ALCON LABORATORIES, INC. (US) | 1999-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261693-A1 | METHOD FOR TREATING CUSHING'S SYNDROME | MC2R, CRH, CRHR2 | ALDH1A1 4128/4885HPGD 1114/4885HSD17B10 242/4885 |
| US-20110224179-A1 | MEDICAMENT AND METHOD OF DIAGNOSIS | CRH, SHBG, MC2R | ALDH1A1 2973/4885HPGD 1112/4885HSD17B10 203/4885 |
| US-11969435-B2 | Concomitant administration of glucocorticoid receptor modulators and CYP3A inhibitors | NR3C1, NR3C2, CYP3A5 | ALDH1A1 602/4885HPGD 708/4885HSD17B10 332/4885 |
| US-20100179115-A1 | USE OF A GLUCOCORTICOID RECEPTOR II ANTAGONIST TO TREAT DEPRESSION IN PATIENTS TAKING IL-2 | CRHR2, IL2, GRIA2 | ALDH1A1 3275/4885HPGD 700/4885HSD17B10 780/4885 |
| US-20160067264-A1 | MEDICAMENT AND METHOD OF DIAGNOSIS | CRH, SHBG, MC2R | ALDH1A1 3099/4885HPGD 1143/4885HSD17B10 179/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.